// App-Quantinova.ai

BSH2020‐PO‐124 : INSIGHT MM study of routine clinical practice in multiple myeloma: analysis of duration of therapy and treatment sequencing in UK patients

Researchers

Presenter

  • G. Cook

Principal Investigators

  • J. Ashcroft

  • K. Boyd

  • M. Garg

  • R. Hall

  • B. Kishore

  • S. Moore

  • D. Smith

  • N. Crofts

  • K. Ren

  • G. Pratt

Medical Centers

  • Leeds Teaching Hospitals NHS Foundation Trust, Leeds

  • Mid Yorkshire Hospitals NHS Foundation Trust, Wakefield

  • Royal Marsden NHS Foundation Trust, London, UK

  • Department of Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Rheumatology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UNITED KINGDOM

  • Nottingham University Hospitals NHS Trust, Nottingham,

  • Takeda UK Limited, High Wycombe, UK

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Prednisone

  • Melphalan

  • Ixazomib

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • NCT02761187

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved